



**HAL**  
open science

## **Mycelia from *Pleurotus* sp. (oyster mushroom): a new wave of antimicrobials, anticancer and antioxidant bio-ingredients**

Humberto J Morris, Yaixa Beltrán, Gabriel Llauradó, Pedro L Batista, Isabelle Gaimé Perraud, Nora Garcia, Serge Moukha, Rosa C Bermúdez, Paul Cos, Edgar Hernández, et al.

### ► To cite this version:

Humberto J Morris, Yaixa Beltrán, Gabriel Llauradó, Pedro L Batista, Isabelle Gaimé Perraud, et al.. Mycelia from *Pleurotus* sp. (oyster mushroom): a new wave of antimicrobials, anticancer and antioxidant bio-ingredients. *International Journal of Phytocosmetics and Natural Ingredients*, 2017, 4 (1), pp.3. 10.15171/ijpni.2017.03 . hal-03504273

**HAL Id: hal-03504273**

**<https://hal.science/hal-03504273v1>**

Submitted on 28 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



# Mycelia from *Pleurotus* sp. (oyster mushroom): a new wave of antimicrobials, anticancer and antioxidant bio-ingredients

Humberto J. Morris<sup>1</sup>, Yaixa Beltrán<sup>1</sup>, Gabriel Llauradó<sup>1</sup>, Pedro L. Batista<sup>2</sup>, Isabelle Perraud-Gaime<sup>3</sup>, Nora García<sup>1</sup>, Serge Moukha<sup>4</sup>, Rosa C. Bermúdez<sup>1</sup>, Paul Cos<sup>5</sup>, Edgar Hernández<sup>6</sup>, José C. Diez<sup>7</sup>

<sup>1</sup>Center for Studies on Industrial Biotechnology, University of Oriente, Cuba

<sup>2</sup>Center of Toxicology and Biomedicine (TOXIMED), Medical University of Santiago de Cuba, Cuba

<sup>3</sup>Mediterranean Institute of Biodiversity and Ecology, Aix Marseille University, France

<sup>4</sup>Laboratory of Toxicology and Applied Hygiene/ INRA, Bordeaux, France

<sup>5</sup>Laboratory for Microbiology, University of Antwerp, Belgium

<sup>6</sup>Department of Biochemistry and Molecular Biology, Dalhousie University, Canada

<sup>7</sup>Department of Biochemistry and Molecular Biology, University of Alcalá de Henares, Spain

## Correspondence to

Humberto J. Morris  
Email:  
morrihumberto@gmail.com

Received 28 December 2016

Accepted 22 April 2017

Published 24 May 2017



## Abstract

**Background** - There has been an upsurge of interest in mushrooms, such as *Pleurotus* species, as an important source of bioactive compounds. Mycelia-submerged culture represents a promising approach to search new safe and healthy myco-products with standardized quality in addition to mushroom fruiting bodies.

**Methods** - The study examined the *in vitro* antimicrobial, antitumor and antioxidant activities of a hot-water extract from *Pleurotus* sp. mycelium. The antimicrobial activity was screened through the activation of the microbial autolytic system of four bacteria and four yeast strains. The anti-proliferative effects on NB4 human leukemia cells were measured by flow-cytometry analyses. The antioxidant activity was investigated by the scavenging of DPPH and ABTS radicals, the reducing power and the inhibition of lipid peroxidation.

**Results and discussion** - The extract activated the microbial autolytic system of eight strains: seven autolyzing strains with intensity values (*I*s) ranging from 2.7% in *Candida* sp. to 36.1% in *Saccharomyces cerevisiae*. Thus, the microbial autolytic system of the strains tested (including Gram-positive and Gram-negative bacteria as well as yeasts) could be activated *in vitro* by mycelial extract. *Pleurotus* extract reduced the viability of NB4 leukemia cells, particularly at the concentration of 200 µg/mL to 82% compared to control cells, and induced apoptosis demonstrated by an increase in annexin V-FITC+ cells (25% at 200 µg/mL). At 10 mg/mL, the extract showed the most potent scavenging effects for DPPH and ABTS radicals (96% and 55%, respectively) and the inhibition of lipid peroxidation (52%). The mushroom extract at 5 mg/mL manifested reducing power of 1.105. Although carbohydrates (76.8%, w/w) appear to be the most important bioactive compounds, secondary metabolites, like phenolics, would also contribute to the antioxidant, antimicrobial and anti-proliferative activities.

**Conclusions** - The hot-water extract obtained from *Pleurotus* mycelium, in light of its *in vitro* antimicrobial, antitumor and antioxidant effects could be considered a good candidate for developing nutraceuticals and for designing innovative myco-therapeutics and phytocosmetics applications.

**Keywords:** anticancer, antimicrobials, antioxidant, nutraceuticals, *Pleurotus*, phytocosmetics, phototherapy

## Introduction

The use of mushrooms to improve health represents an important cultural heritage as they have been used since time immemorial as a source of highly tasty/nutritional foods and medicinal preparations by the greatest early civilizations.<sup>1-4</sup> Mushrooms are now attracting more attention as a functional food and as a source of drugs and nutraceuticals.<sup>5-7</sup>

Mushrooms are thought to exert approximately 130 pharmacological functions such as antitumor, immunomodulatory, antigenotoxic, antioxidant, antiinflammatory, hypocholesterolemic, antihypertensive, antiplatelet-aggregating, antihyperglycemic, antimicrobial, and antiviral activities.<sup>8</sup>

Modern scientific data has documented that mushrooms represent an unlimited source of bioactive molecules as an example of molecular diversity with recognized potential in



drug discovery and development.<sup>9</sup> The bioactive molecules comprise high molecular weight compounds, mainly polysaccharides, and low molecular weight secondary metabolites.<sup>10</sup> Polysaccharides (especially  $\beta$ -glucans) are the best known and most potent mushroom derived substances, with antitumor and immunomodulatory effects, thus acting as biological response modifiers (BRMs).<sup>11-12</sup> In addition, the vast structural diversity of mycochemicals (phenolic compounds, terpenes, lactones, steroids, alkaloids, among others) provides unique opportunities for discovering new drugs that target and modulate biochemical signal transduction pathways.<sup>13-15</sup>

Of the known mushroom species, approximately 700 are considered to be safe with medicinal properties.<sup>3</sup> Pharmacological effects have been demonstrated for many traditionally used mushrooms, including species from genera *Ganoderma*, *Lentinus* (*Lentinula*), *Agaricus*, *Auricularia*, *Flammulina*, *Grifola*, *Hericium*, *Pleurotus*, *Trametes* (*Coriolus*), *Schizophyllum*, *Lactarius*, *Phellinus*, *Cordyceps*, *Inonotus*, *Inocybe*, *Tremella*, and *Russula*.<sup>2,14,16-17</sup> In this wonderful world, *Ganoderma*, mushroom of immortality, has been considered the king of medicinal mushrooms, followed by *Lentinula* and others, including *Pleurotus*.<sup>7</sup>

On the other hand, with the increasing concern of public health and consumers' awareness, there has been a metamorphosis in the cosmetic industry with natural products being more in demand than their synthetic counterparts.<sup>18</sup> Natural ingredients could be an attractive candidate in cosmetic formulation due to: (a) antimicrobial activities could protect against the growth of microorganisms in cosmetics and skin and thus, minimize or replace the use of synthetic preservatives in cosmetics, and (b) antioxidant properties could protect the cells from aging caused by the oxidative damage of free radicals and enhance skin nutrition.<sup>19</sup> In this context, mushrooms and their products are now finding their way into cosmetics and purported as highly active ingredients in these products.<sup>20</sup> Nutritive, anti-inflammatory, regenerative and antioxidant properties of several mushrooms makes their usage prospective in manufacturing of cosmetic products. There are numerous potential medicinal products from mushrooms that could be used in cosmeceuticals (products applied topically, such as creams, lotions, and ointments) or nutricosmetics (products that are ingested orally). The mushrooms presently used are traditionally known to produce medicinal compounds and thus were the first to be incorporated in cosmetic applications.<sup>21</sup>

Species of the genus *Pleurotus* (Fries) Kummer (Basidiomycota, Agaricales) (Figure 1), like many edible and medicinal mushrooms, are a good source of antitumor, immunostimulating, antimicrobial and antioxidant substances besides a wide array of biotechnological and environmental applications.<sup>7,22-23</sup> Usually regarded as oyster mushrooms, these edible basidiomycetes are among the most popular worldwide, as much as they achieved the third position in the production of edible mushrooms, behind the species of the genus *Agaricus* and *Lentinula*.<sup>24</sup> More recently, extensive research has been done on isolation and characterization of new functional compounds, besides the in-depth study of their medicinal properties.<sup>7,25-28</sup>



**Figure 1:** Production of *Pleurotus* sp. (oyster mushroom) in the research-development plant of the Center for Studies on Industrial Biotechnology (CEBI) (a), and *Pleurotus* fruiting bodies (strain CCEBI-3024) after harvesting.

Both fruiting bodies and mycelia of *Pleurotus* spp. have been studied in search of biological effector molecules.<sup>29-30</sup> However, between 80% and 85% of all medicinal mushroom products are derived from fruiting bodies; only 15% of all products are based on extracts from mycelia.<sup>31</sup> For this reason, mushroom mycelia may also constitute a good source of healthy compounds, which may be useful in the formulation of nutraceutical, medicinal and cosmetic products.

In previous studies, we reported the immunomodulating activity of a hot-water mycelial extract from *Pleurotus ostreatus* against the immunosuppression caused by cyclophosphamide or whole-body irradiation in mice.<sup>32-33</sup> To our knowledge, this is the first report linking some bioactivities of *Pleurotus*' mycelia with their potential applications in phyto- (myco-) cosmetics. Better insight into the different roles of multiple active compounds and the mechanisms underlying their biological action will accelerate commercial production of novel pharmaceuticals and cosmetic products based on water-extracts from mycelia of *Pleurotus* sp.


## Materials and methods

### *Pleurotus* sp. strain and preparation of hot-water mycelial extract

*Pleurotus* sp. strain (CCEBI-3024) is deposited at the Culture Collection of the Center of Studies for Industrial Biotechnology (CEBI, Cuba). The strain was maintained on slants with solid medium of potato dextrose agar (PDA) incubated at 5°C.

Mycelium was inoculated in Erlenmeyer flasks, which contained YPG medium (yeast-peptone-glucose). The flasks were incubated at 27°C with continuous stirring at 100 rpm for 15 days. After the submerged fermentation was carried out, *Pleurotus* sp. mycelia were collected by centrifugation at 4000 g and washed twice with distilled water. Isolated mycelia, suspended in 200 g (wet weight)/L of distilled water, were extracted with boiling water for 10 h and the final extracts were collected by centrifugation and filtration.<sup>26</sup> Figure 2 shows a simple production platform for mushroom extract using submerged mycelium fermentation.

The extracts (F-I) at a yield of 5.5 g/L culture (dried weight) were stored at -20°C and freeze dried. They are composed of 76.8% of carbohydrate, 15% of protein, 0.11% of nucleic acids, and 5% of minerals. The presence of different secondary metabolites such as phenolic compounds, i.e. flavonoids and



**Figure 2:** Process for mushroom extract production by *Pleurotus* sp. using submerged mycelium fermentation.

tannins, and alkaloids has also been demonstrated in *Pleurotus* mycelia-derived hot water extract.<sup>34</sup>

#### Determination of antimicrobial activity

The antimicrobial activity of *Pleurotus* mycelial extract was determined through its ability to activate the autolytic enzyme system of the microbial cell.<sup>35</sup> Four bacterial strains (*Bacillus cereus* ATCC 11776, *Bacillus subtilis* ATCC 6633, *Staphylococcus aureus* ATCC 25953 and *Pseudomonas aeruginosa* ATCC 27853) as well as four yeast strains (*Candida* sp. CCEBI 2034, *Candida intermedia* CCEBI 2034, *Saccharomyces cerevisiae* CCEBI 2010 and *Saccharomyces fermentii* CCEBI 2008), were used as test microorganisms. Suspensions of microbial cells were prepared in distilled water to an absorbance at 520 nm of approximately 1.0 (Genesys 10 uv, Thermospectronic Rochester, NY, USA) and were mixed with equal quantities of the *Pleurotus* extract at 2.4 mg/mL. This concentration was chosen taking into account the lack of antimicrobial effects found with lower double-diluted concentrations of *Pleurotus* extract ranging from 0.5 to 2 048 µg/mL, using the agar-well diffusion technique and the resazurine reduction test (data not shown).

Controls were distilled water only. Absorbance at 520 nm of this mixture was measured at zero time ( $D_0$ ) and after their exposure for 60 min at 37°C ( $D_{60}$ ). The antimicrobial activity, expressed as the intensity of autolysis (I) in both the study and control samples, was calculated using the formula:

$$I = \frac{D_0 - D_{60}}{D_0} \times 100\%$$

For naturally non-autolyzing strains  $I_c > 0$ , whereas for naturally non-autolyzing strains  $I_c = 0$ .

#### Apoptosis induction in human acute promyelocytic leukemia (NB4) cells

The cells were maintained in RPMI medium (Gibco-Life Technologies) with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 0.02 mg/mL gentamycin. Cells were cultured at 37°C in a humidified air atmosphere with 5% CO<sub>2</sub>. Apoptosis induction was evaluated by the Annexin V-FITC assay measuring the Phosphatidylserine exposure on the outer side of membrane. For this assay,  $5 \times 10^5$  treated cells were collected and centrifuged at 1500 rpm for 3 min. Then, they were incubated for 15 min in the dark at room temperature in 500 µL PBS containing 10 µL of binding reagent and 1.25 µL Annexin V-FITC (Annexin V-FITC Apoptosis Detection Kit, Calbiochem, EMD Millipore, USA). Subsequently, the cells were centrifuged at 2300 rpm for 5 min and resuspended in 500 µL binding buffer 1× diluted in PBS. After that, 10 µL PI was added and the samples were analyzed in a FACScan cytometer (Becton Dickinson, San José, CA, USA). Data were analyzed using WinMDI 2.8 software. All Annexin V<sup>+</sup>/PI<sup>-</sup> cells were scored as early apoptotic, while double-stained Annexin V<sup>+</sup>/PI<sup>+</sup> cells were considered as late apoptotic.

#### Assays for in vitro antioxidant activity

**DPPH assay.** Radical scavenging ability (RSA) of mushroom extract against 1,1-diphenyl-2-picryl-hydrazyl (DPPH, Sigma-Aldrich) was measured according Cheung *et al.*<sup>36</sup> using spectrophotometry. The extract (1 mL) at 10 mg/mL was mixed with 0.5 mL of 0.1 mM DPPH ethanolic solution. Then, the mixture was shaken vigorously and incubated at 25°C for 1 h in the dark. The absorbance of the sample was measured at 520 nm (VIS-723G spectrophotometer, Beijing Rayleigh Analytical Instrument Corporation) and the scavenging ability against DPPH radicals was calculated as a percentage of DPPH discoloration using the equation:

$$\% \text{ RSA} = [(A_{\text{DPPH}} - A_s) / A_{\text{DPPH}}] \times 100$$

where  $A_s$  is the absorbance in the solution when the sample extract has been added, and  $A_{\text{DPPH}}$  is the absorbance of DPPH solution. L-ascorbic acid was used as a standard.

**ABTS assay.** Scavenging effect on 2,2-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS, Sigma-Aldrich) radicals was measured according to Choi *et al.*<sup>37</sup> ABTS radicals were generated by mixing 7 mM of the ABTS stock solution and 2.45 mM of potassium persulfate (Sigma-Aldrich) in distilled water, and storing this mixture overnight at room temperature in the dark. The mixture (10 mL) was diluted with 840 mL of distilled water. *Pleurotus* extract (50 µL) at 10 mg/mL was added to 3 mL of ABTS solution and after

90 min, the absorbance was measured at 414 nm (VIS-723G spectrophotometer, Beijing Rayleigh Analytical Instrument Corporation). The scavenging ability against ABTS radicals was calculated using the equation:

$$\% \text{ RSA} = [(A_{\text{ABTS}} - A_s) / A_{\text{ABTS}}] \times 100$$

where  $A_s$  is the absorbance in the solution when the sample extract has been added, and  $A_{\text{ABTS}}$  is the absorbance of ABTS solution. L-ascorbic acid was used as a standard.

**Reducing power.** The reducing power was determined according to the method of Huang and Mau.<sup>38</sup> The mushroom extract (2.5 mL) at 5 mg/mL was mixed with 2.5 mL of 10 g/L potassium ferricyanide (Sigma-Aldrich) and the mixture was incubated at 50°C for 20 min. Then 2.5 mL of 100 g/L trichloroacetic acid (Merck) was added, and the mixture was centrifuged at 2 000 g for 10 min. A sample of the supernatant (5 mL) was mixed with 5 mL of distilled water and 1 mL of 1 g/L  $\text{FeCl}_3$  (Merck), and the absorbance was measured at 700 nm (VIS-723G spectrophotometer, Beijing Rayleigh Analytical Instrument Corporation). Butylated hydroxytoluene (BHT) was used as a standard.

**Determination of inhibitory activity on lipid peroxidation.** A reaction mixture containing 8 mL of a suspension of 20% sheep erythrocytes, 7.52 mL of physiological saline, 80  $\mu\text{L}$  of 0.5 mol/L  $\text{FeCl}_3$ , 0.4 mL of ascorbic acid (0.5 mM) and 1 mL of mycelial extract (10 mg/mL) was incubated at 37°C in a water bath for 120 min. The lipid peroxide formed was estimated by measuring thiobarbituric acid reacting substances (TBARS) with some modifications.<sup>39</sup> For this, 2 mL of the incubation mixture was treated with 1 mL of trichloroacetic acid at 10% and the samples were shaken in a vortex for 1 min and centrifuged at 6000 g for 15 min. Then, 2 mL of the supernatant was transferred to test tubes with 2.5 mL of 0.335% thiobarbituric acid (TBA) and the reaction tube was kept in a water bath at 100°C for 1 h. After cooling, the absorbance was measured at 532 nm. The percentage of inhibition of lipid peroxidation was determined by comparing the results of the test compounds (treated with mushroom extract) with those of control (not treated with the mushroom extract). The % of lipid peroxide-scavenging ability of the extract was calculated by the formula described in DPPH and ABTS radicals scavenging effect.

### Statistical analysis

Experimental results were mean  $\pm$  SD of three measurements. The values  $p < 0.05$  were regarded as significant. Statistical analysis of the data was performed by the Mann-Whitney test or the Kruskal-Wallis rank test followed by the Student-Newman-Keuls test to determine the significance of differences between treatments. The software Statgraphics Plus version 5.1 (Statistical Graphics Corporation, 1994-2001) was used in all the analysis.

### Results and discussion

The wide spectrum of natural products with biological activity produced by Basidiomycetes includes antimicrobial agents, as well as immunomodulatory, antioxidant and anti-proliferative activities, and some have already been clinically applied.<sup>40</sup> To broaden their use in food, cosmetic and phar-


maceutical industries, a comprehensive study of the effects exerted as biological response modifiers is still needed. Thus, in order to expand the properties of a hot water mycelial extract from *Pleurotus* sp. as a natural ingredient, we screened for several activities in this study, and found that it showed: (i) antimicrobial activity as judged by its ability to activate the microbial autolytic system; (ii) antiproliferative activity of NB4 leukemia cells and ability to induce apoptosis; and (iii) *in vitro* antioxidant activity in view of the degree of lipid peroxidation inhibition and the free radical scavenging ability. All of these activities suggested it to be a good candidate for developing innovative myco-cosmetic and other health-care biotech-based products.

### Antimicrobial activity of *Pleurotus* sp. hot-water mycelial extract

Antimicrobial ingredients are materials that protect against the growth of microorganisms in cosmetics and skin, including bacteria, viruses and fungi. They can also kill organisms that may be present in ingredients that may be used to make cosmetics and thus, play an important role in making sure that cosmetics are free of microorganisms during storage and after they are opened.<sup>41</sup>

Clinical microbiologists have two reasons to be interested in the topic of antimicrobial natural extracts. First, it is very likely that these phytochemicals will find their way into the arsenal of antimicrobial drugs prescribed by physicians; several are already being tested in humans. Second, the public is becoming increasingly aware of problems with the overprescription and misuse of traditional antibiotics.<sup>42</sup>

The antimicrobial activity was screened through the ability of mushroom extract to activate the microbial autolytic system of eight strains (4 bacteria and 4 yeast strains) (Figure 3). Autolysis of seven naturally autolyzing strains ( $I_c > 0$ ) was activated with intensity values ( $I_s$ ) ranging from 2.7% in *Candida* sp. to 36.1% in *S. cerevisiae*. Among the tested bacterial autolyzing strains, the highest  $I_s$  was showed in the Gram-positive *B. subtilis*. On the other hand, autolysis was of 1.8% in one naturally non-autolyzing strain (*B. cereus*), for which  $I_c = 0$ . Although the control of autolysin activity still remains a mystery, strategies for lysing microbes by direct activation of their autolytic system are among the possi-



**Figure 3:** Intensity of autolysis ( $I_s$ ) of microbial strains achieved when using a hot-water mycelial extract from *Pleurotus* sp. Results are showed as means  $\pm$  standard deviation of three replicates; means with different letters indicate statistically significant differences according to the Kruskal-Wallis rank test followed by the Student-Newman-Keuls test ( $p < 0.05$ ).

ble approaches for antimicrobial drug development.<sup>35</sup> In our study, the microbial autolytic enzyme system of the strains tested (including Gram-positive and Gram-negative bacteria as well as yeasts) could be activated *in vitro* by *Pleurotus* mycelial extract.

Many secondary metabolites isolated from edible mushrooms have shown potentialities as antimicrobial agents. In this context, *Pleurotus* spp. extracts have been explored to combat simple and multiple drug resistant microbial strains.<sup>43</sup> Antimicrobial activity of oyster mushroom depends upon the nature of the solvent.<sup>12</sup> Although in some cases ethanol extracts contain more bioactive substances and potent effects, the results for *Pleurotus* spp. are contradictory. Our results compare favorably with those reported for an ethanolic extract of lyophilized mycelium of *P. ostreatus* PQMZ91109 when cultured in presence of the same nitrogen source (yeast extract and peptone).<sup>44</sup>


The presence of secondary metabolites like phenolic compounds ( $38 \pm 5$  mg/g) such as flavonoids and tannins, and alkaloids was demonstrated in the *Pleurotus* hot-water mycelial extract tested here.<sup>34</sup> The phenolic constituents of *Pleurotus* spp. may also elicit antibacterial activity as found in many medicinal plants with mechanisms of action characterized by cell membrane lysis, and the inhibition of protein synthesis, proteolytic enzymes and microbial adhesion.<sup>45</sup> These bioactive substances would also contribute to the antimicrobial activity of the extract.

#### Antiproliferative activity of NB4 leukemia cells and apoptosis induction

Since research has tended to focus on the dietary value of species of the genus *Pleurotus*, there is relatively little information pertaining to their anticancer mechanisms, particularly in mycelia derived products.<sup>46</sup> In this study, the treatment with *Pleurotus* mycelial extract reduced viability of NB4 human leukemia cells, particularly at the concentration of 200 µg/mL, to 82% with respect to control untreated cells ( $p < 0.05$ ) (data not shown). The extract also induced apoptosis of NB4 cells, which was demonstrated by an increase in the number of annexin V-FITC positive cells, mostly at the dose of 200 µg/mL (25%,  $p < 0.05$ ) (Figure 4).

Apoptosis is the physiological controlled process by which cells actively commit a gene-mediated cell death program essential for cell homeostasis. It is also the key mechanism for acting the chemotherapeutic agents.<sup>47</sup> The apoptosis percentage values obtained in this work were lower compared to those reported for *P. ostreatus* mycelia-derived proteoglycans (5 mg/kg) in the *in vivo* Sarcoma-180-bearing mouse model (45.36%-75.36%).<sup>48</sup> However, the apoptosis ratios achieved in our study were higher than those referenced by Lee *et al.*<sup>49</sup> on Molt 4 human leukemia cells treated with 1 mg/mL of the polysaccharopeptide PSP isolated from the mycelia of *Trametes (=Coriolus) versicolor* ( $5.92 \pm 0.7\%$ ). Taking into account that the evasion of apoptosis is a hallmark of human cancers (e.g., hematological malignancies),<sup>47</sup> products capable of inducing apoptosis deserve special interest.

In this respect, some mushrooms and their extracts are either presently investigated to be used as promising anti-cancer products for their antiproliferative effects on certain



**Figure 4:** Induction of apoptosis in human leukemia NB4 cells treated with the *Pleurotus* sp. mycelial extract for 24 h at concentrations of 100 and 200 µg/mL (a), and a flow-cytometry profile of cell cycle of treated NB4 cells with 200 µg/mL (b). The cell populations shown in the right bottom quadrant (PI-/Annexin V+) represents early apoptotic cells, whereas the right upper quadrant (PI+/Annexin V+) represents late apoptotic cells. The values in (a) represent the mean of three different experiments. Different letters indicate significant differences among the groups according to the Kruskal-Wallis rank test followed by the Student-Newman-Keuls test ( $p < 0.05$ ).

skin cancers. *L. edodes* has been shown to reduce cell proliferation and induce apoptosis in CH72 mouse skin carcinoma cells via an induction of a transient G<sub>1</sub> arrest.<sup>50</sup> Similarly, reduction of cell proliferation of B-16 melanoma cells by arrest in the G<sub>0</sub>/G<sub>1</sub> phase of the cell cycle, followed by both apoptotic and secondary necrotic cell death has been demonstrated for a methanol extract of *C. versicolor*.<sup>51</sup>

#### In vitro antioxidant activities

Until now, research has tended to focus on the dietary significance of edible mushrooms; however, there is relatively little information relating to the antioxidant activity and the possible use of such mushrooms to neutralize oxidative stress.<sup>52</sup>

The antioxidant potential of a compound could be attributed to its various characteristics, the most important of these being the ability to scavenge and reduce free radicals, to chelate transition metal ions, to inhibit lipid peroxidation, among others.<sup>53</sup> DPPH free radical scavenging activity assay is one of the most common methods for the determination of antioxidant capacity. As the data presented in Table 1 show, the DPPH radical scavenging activity of an aqueous extract obtained from *Pleurotus* mycelium was of 96%, similar to the values achieved with ascorbic acid used as control. Scavenging effects of extracts from several specialty

**Table 1:** *In vitro* antioxidant activity of a hot-water mycelial extract of *Pleurotus* sp.

Sample	Scavenging of DPPH radicals (%)	Scavenging of ABTS radicals (%)	Reducing power (A <sub>700nm</sub> )	Inhibition of lipid peroxidation (%)
<i>Pleurotus</i> extract (10 mg/mL)	96.0 ± 0.4	55.0 ± 0.8	1.105 ± 0.022*	52.2 ± 0.4
Control (ascorbic acid)	96.3 ± 0.6	98.0 ± 0.2*	0.700 ± 0.018 (BHT)	92.1 ± 0.4*

Results are shown as means ± standard deviation of three replicates; means with an (\*) differ when compared with the *Mann-Whitney* test ( $p < 0.05$ ).

and commercial mushrooms on DPPH radicals augmented with increased extract concentrations. Thus, DPPH radical scavenging activity varied from 9% (*P. nebrodensis*) to 57% (*P. cystidiosus*). Moreover, DPPH scavenging action for *P. citrinopileatus* and some other fungi significantly improved with the gradual elevation of sample concentration from 0.5 to 9.0 mg/mL.<sup>54</sup>

With the ABTS radical scavenging test, we can measure the activity of hydrophilic and lipophilic compounds; therefore, it is useful in the simultaneous study of several natural ingredients.<sup>55</sup> In this study, the ABTS radical scavenging activity of an aqueous extract obtained from *Pleurotus* mycelium at 10 mg/mL was of 55%, lower than those of 80% reported for a fruiting bodies extract (Table 1).<sup>56</sup> On the other hand, hydro-alcoholic extracts of *Grifola gargar* showed an ABTS radical scavenging ability of 90.9-93.3 ascorbic acid equivalents (mg of ascorbic acid per L of sample).<sup>57</sup> This method has been also used in the evaluation of the antioxidant activity of neutral polysaccharides from *Auricularia auricular* and their homologues sulfated in the concentrations of 0.2-10 mg/mL, without significant differences.<sup>58</sup>

Moreover, it has been discussed that the diphenylpropane structure of flavonoids and the aromatic ring structure of phenolics, such as aromatic oxy phenol acids, might contribute to the free radical scavenging ability of these compounds.<sup>59</sup>

The reducing capability of a compound may serve as a significant indicator of its potential antioxidant activity and the efficacy of certain antioxidants is known to be associated with their reducing power.<sup>60</sup> In the present study, the reducing power of a 5 mg/mL concentration of the mushroom extract was found to be 1.107, which was relatively more pronounced than that of BHT (0.7) ( $p < 0.05$ ) (Table 1). The reducing power of medicinal mushrooms might be due to their hydrogen-donating ability.<sup>52</sup> Possibly, medicinal mushrooms contain high amounts of reductones, which could react with radicals to stabilize and terminate radical chain reactions. The reducing power of the ethanolic extract of *P. ostreatus* fruiting bodies was found to steadily increase in direct proportion to the increasing concentration of the extract. The reducing power of a 10 mg/mL concentration of the mushroom extract was found to be 1.367, which was relatively higher than that of BHT (1.192).<sup>61</sup> Further ethanolic extract from the fruiting bodies of the mushroom *Pleurotus citrinopileatus* has been reported to exhibit the reducing power of 1.05 at 10 mg/mL.<sup>38</sup>

Lipid peroxidation (LPO), a process induced by free radicals, leads to oxidative deterioration of polyunsaturated lipids and inactivates cellular components and therein plays a key role in oxidative stress in biological systems.<sup>62</sup> Hence, the inhibitory activity of the mushroom extract on LPO was evaluated. Both the mushroom extract and the ascorbic acid standard inhibited lipid peroxidation (Table 1). At a concentration of 10 mg/mL, the mushroom extract effected 52% inhibition of LPO activity and the ascorbic acid standard effected 92%. At least until we know, there is no data available for comparison of our results obtained with *Pleurotus* mycelial extract on lipid peroxidation in the *in vitro* erythrocyte membrane model estimated by TBARS. Erythrocytes are excellent subjects for studies of biological effects of free

radicals, since they are structurally simple, are continuously exposed to high oxygen tensions, the membrane lipids are composed partly of polyunsaturated fatty acid side chains which are vulnerable to peroxidation, and they have antioxidant enzyme systems.<sup>63</sup>

An ethanolic extract of *P. ostreatus* at a concentration of 10 mg/mL effected 56.20% inhibition of LPO activity of rat liver homogenate, and the ascorbic acid standard effected 67.15%. The concentration of the extract and ascorbic acid needed for 50% inhibition of LPO was 8 and 6 mg/mL, respectively. Moreover, the pronounced antioxidant activity of *P. ostreatus* mushroom, manifested as inhibition of lipid peroxidation (LPO), scavenging of hydroxyl and superoxide radicals, reducing power and chelating activity on ferrous ions, has been related with its high phenolic content.<sup>52</sup> Therefore, the *in vitro* antioxidant properties exhibited by the tested *Pleurotus* mushroom preparation may be due to the presence of these antioxidant mycochemicals inherent in it. In addition, the antioxidant activities (chelating ability of ferrous ion, inhibition of LPO and reducing power) found in polysaccharide extracts from the widely used mushrooms *Ganoderma applanatum*, *Ganoderma lucidum*, *Lentinus edodes* and *Trametes versicolor*<sup>64</sup> does not discard the possible contribution of  $\beta$ -1,3-1,6-glucans polysaccharides to the antioxidant effect. Actually, mushroom extracts that are rich in antioxidant components will have high potential to be developed into cosmetic formulations. For example, schizophyllan derived from *Schizophyllum commune* contains  $\beta$ -1,6-branched- $\beta$ -1,3-glucan, decreases inflammation, irritation and other damage due to UV and toxic environment exposure of the skin.<sup>21</sup>

There are numerous potential mycochemicals from mushrooms that could be used in cosmeceuticals or nutraceuticals. The main families of mycochemicals previously reported in the hot-water extract from *Pleurotus* mycelia tested here are listed in Table 2, with their biological activities experimentally verified in our laboratory or in agreement with other mushroom studies.

Species presently used, or patented to be used, in cosme-

**Table 2:** Mycochemical profile and activities - verified in our laboratory or in agreement with other mushroom studies - of mycelial extract of *Pleurotus ostreatus*.

Carbohydrates/ Glycosides	Molisch	++	Immunomodulatory, antitumor, antimicrobial, antioxidant
Reducing Sugar	Fehling	+	
Quinones	Benedict	+	
	Borntrager	-	
Phenols and tannins	FeCl <sub>3</sub>	+	Antioxidant, anti-inflammatory, antimicrobial
Amino acids	Ninhydrine	++	Structural units of proteins (immunomodulatory, antioxidant, antimicrobial)
Flavonoids	Concentrated H <sub>2</sub> SO <sub>4</sub>	+	Antioxidant, antimicrobial, anti-inflammatory
	Rosenheim	+	
(-) none, (+) present, (++) mild, (+++) marked			

ceuticals and nutricosmetics include *Agaricus subrufescens* (= *A. blazei*, *A. brasiliensis*), *Choiromyces maeandriiformis*, *Cordyceps sinensis*, *Ganoderma lucidum*, *Grifola frondosa*, *Hypsizyguis ulmarius*, *Inonotus obliquus*, *Lentinula edodes*, *Polyporus* spp., *Trametes versicolor*, *Tremella fuciformis*, *Schizophyllum commune* and many other lesser used taxa.<sup>65</sup> However, there are numerous other mushroom species that are untested, undescribed or not yet cultivatable and that have huge potential for use in the cosmetic industry. To our knowledge, there is only one cosmetic product formulated with *Pleurotus ostreatus* (fruiting bodies) and *Ganoderma lucidum*: Hankook Sansim Firming Cream (Tan Ryuk SANG, Korea) which makes skin tight and vitalized.<sup>21,66</sup> Therefore, it is not surprising that intrinsic biological properties demonstrated *in vitro* in our study with *Pleurotus* mycelial extract can be transferred *in vivo* after mushroom use as food, nutraceutical or cosmeceutical/nutricosmetic.

### Conclusions

It may be concluded that in view of the above results, the mycelial hot-water extract from *Pleurotus* sp. could be used as a natural ingredient with antimicrobial, anticancer and antioxidant properties, thus representing a potential alternative to some commercially available synthetic products, which may have a large number of side effects. The various experiments conducted revealed it to be a very good source of mycochemicals that could play—owing to their synergistic action—a very important role in drug development and as a health supplement. With interdisciplinary studies, this mushroom extract can find its way into cosmetics for its prospective usage in cosmeceuticals and nutricosmetics. Further research is also required for isolation and identification of active biomolecules and principles present in these extracts, so that they could be exploited at the industrial scale.

### Conflict of interest

The authors declare no conflict of interest.

### Acknowledgements

The authors would like to thank the Cuban Ministry of Science, Technology and Environment (Territorial Project 9072 of the Program for Development of Health Products, CITMA). This work has also been supported by the Belgian Development Cooperation through VLIR-UOS (Flemish Interuniversity Council-University Cooperation for Development) in the context of the Institutional University Cooperation Program with University of Oriente. The authors also thank the “Biotechnologie de *Pleurotus* sp. à Cuba et diversification de sa Culture pour des Applications Environnementales et Nutraceutique” (FSP Coopération Scientifique Franco-Cubaine) project and the IRD under the Programme Jeunes Equipes AIRD (JEAI).

### References

1. Pereira E., Barros L., Martins A., Ferreira ICFR. Towards chemical and nutritional inventory of Portuguese wild edible mushrooms in different habitats. *Food Chem.* 2012;130:394-403. doi:10.1016/j.foodchem.2011.07.057.
2. Stamets P. *MycMedicinals: An Informational Treatise on Mushrooms*, 3rd ed. Olympia, WA: MycoMedia Productions; 2002.
3. Wasser SP. Medicinal mushroom science: history, current status, future trends, and unsolved problems. *Int J Med Mushr.* 2010;12:1-16.
4. Wasser SP, Weis AL. Medicinal properties of substances occurring in higher Basidiomycetes mushrooms: current perspectives (Review). *Int J Med Mushr.* 1999;1,31-62.
5. Chang ST. Medicinal mushroom products: nutraceuticals and/or pharmaceuticals? *ACTA Edulis Fungi* 2009;16:80-86.
6. Ferreira ICFR, Barros L., Abreu RMV. Antioxidants in wild mushrooms. *Curr Med Chem.* 2009;16:1543-1560. doi:10.2174/092986709787909587.
7. Patel Y., Naraian R., Singh VK. Medicinal properties of *Pleurotus* species (Oyster Mushroom): a review. *World J Fungal Plant Biol.* 2012;3:1-12. doi:10.5829/idosi.wjfpb.2012.3.1.303.
8. Wasser SP. Medicinal mushroom science: current perspectives, advances, evidences, and challenges. *Biomed J.* 2014;37:345-356. doi:10.4103/2319-4170.138318.
9. Badalyan SM. Potential of mushroom bioactive molecules to develop healthcare biotech products. In: *Proceedings of the 8th International Conference on Mushroom Biology and Mushroom Products (ICMBMP8)*, New Delhi, India, 2014. p. 373-378.
10. De Silva DD, Rapior S, Sudarman E, *et al.* Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry. *Fungal Diversity* 2013;62:1-40. doi: 10.1007/s13225-013-0265-2.
11. Wasser SP. Medicinal mushrooms as a source of anti-tumor and immunomodulating polysaccharides. *Appl Microbiol Biotechnol.* 2002;60:258-274. doi:10.1007/s00253-002-1076-7.
12. Zhang M., Cui S., Cheung P., Wang Q. Antitumor polysaccharides from mushrooms: a review on their isolation process, structural characteristics and anti-tumor activity. *Trends Food Sci Technol.* 2007;18:4e19. doi:10.1016/j.tifs.2006.07.013.
13. Chang ST, Wasser SP. The role of culinary-medicinal mushrooms on human welfare with a pyramid model for human health. *Int J Med Mushr.* 2012;14:95-134.
14. Patel S., Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: a review. *3 Biotech* 2012;2:1-15. doi:10.1007/s13205-011-0036-2.
15. Zaidman B., Yassin M., Mahajna J., Wasser SP. Medicinal mushrooms: modulators of molecular targets as cancer therapeutics. *Appl Microbiol Biotechnol.* 2005;67:453-468. doi: 10.1007/s00253-004-1787-z.
16. Lindequist U., Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms. *Evid-Based Compl Alt Med.* 2005; 2:285-299. doi:10.1093/ecam/neh107.



17. Vikineswary S., Chang ST. Edible and medicinal mushrooms for sub health intervention and prevention of lifestyle diseases. *Tech Monitor* 2013;Jul-Sep:33-43.
18. Neem Associations. Neem Leaf, Jun 19, 2010, from <http://www.neem-products.com/neem-leaves.html>. (Accessed Jun 8, 2016).
19. Lupo MD, Mary P. Antioxidants and Vitamins in Cosmetics. *Clin Dermatol.* 2001;19: 467-473. [doi:10.1016/S0738-081X\(01\)00188-2](https://doi.org/10.1016/S0738-081X(01)00188-2).
20. Lemann P. Mushrooms in cosmetics. *SpecialChem Cosmetics and Personal Care, Innovations and Solutions*, February 2007.
21. Hyde KD, Bahkali AH, Moslem MA. Fungi—an unusual source for cosmetics. *Fungal Diversity* 2010;43:1-9. [doi:10.1007/s13225-010-0043-3](https://doi.org/10.1007/s13225-010-0043-3).
22. Gregori A., Švagel M., Pohleven, J. Cultivation techniques and medicinal properties of *Pleurotus* spp. *Food Technol Biotechnol.* 2007;45:238-249.
23. Gomes-Corrêa RC, Brugnari T, Bracht A, Peralta RM, Ferreira ICFR. Biotechnological, nutritional and therapeutic uses of *Pleurotus* spp. (Oyster mushroom) related with its chemical composition: a review on the past decade findings. *Trends Food Sci Technol.* 2016;50:103-117. [doi:10.1016/j.tifs.2016.01.012](https://doi.org/10.1016/j.tifs.2016.01.012).
24. Fernandes A., Barros L., Martins A., Herbert P., Ferreira ICFR. Nutritional characterisation of *Pleurotus ostreatus* (Jacq. ex Fr.) P. Kumm. produced using paper scraps as substrate. *Food Chem.* 2015;169:396-400. [doi:10.1016/j.foodchem.2014.08.027](https://doi.org/10.1016/j.foodchem.2014.08.027).
25. Khan A, Tania M. Nutritional and medicinal importance of *Pleurotus* mushrooms: an overview. *Food Rev. Int.* 2012;28:313-329. [doi:10.1080/87559129.2011.637267](https://doi.org/10.1080/87559129.2011.637267).
26. Morris HJ, Llauradó G., Beltrán Y., Lebeque Y., Fontaine R., Bermúdez RC, Rodríguez S. Procedimiento para la obtención de un preparado inmunocéutico de *Pleurotus* spp. Certificado No. 23717 (Resolución 1754/2011) Ref: 2011/1337; 2011 (in Spanish)
27. Yahaya NFM, Rahman MA, Abdullah N. Therapeutic potential of mushrooms in preventing and ameliorating hypertension. *Trends Food Sci Technol.* 2014;39:104-115. [doi:10.1016/j.tifs.2014.06.002](https://doi.org/10.1016/j.tifs.2014.06.002).
28. Llauradó G, Morris HJ, Lebeque Y, et al. Oral administration of an aqueous extract from the oyster mushroom *Pleurotus ostreatus* enhances the immunonutritional recovery of malnourished mice. *Biomed Pharmacother.* 2016;83:1456-1463. [doi:10.1016/j.biopha.2016.08.067](https://doi.org/10.1016/j.biopha.2016.08.067).
29. Llauradó G., Morris HJ, Lebeque Y., et al. Phytochemical screening and effects on cell-mediated immune response of *Pleurotus* fruiting bodies powder. *Food Agric Immunol.* 2013;24(3):295-304. [doi:10.1080/09540105.2012.686988](https://doi.org/10.1080/09540105.2012.686988).
30. Refaie FM, Esmat AY, Daba AS, Taha SM. Characterization of polysaccharopeptides from *Pleurotus ostreatus* mycelium: assessment of toxicity and immunomodulation *in vivo*. *Micol Apl Int.* 2009;21:67-75.
31. Barros L., Baptista P., Estevinho LM, Ferreira I. Bioactive properties of the medicinal mushroom *Leucopaxillus giganteus* obtained in the presence of different nitrogen sources. *Food Chem.* 2007;105:179-186. [doi:10.1016/j.foodchem.2007.03.063](https://doi.org/10.1016/j.foodchem.2007.03.063)
32. Morris HJ, Marcos J, Llauradó G., et al. Immunomodulating effects of hot-water extract from *Pleurotus ostreatus* mycelium on cyclophosphamide treated mice. *Micol Apl Int.* 2003;15:7-13.
33. Llauradó G., Morris HJ, Tamayo V., et al. Haematopoiesis radioprotection in Balb/c mice by an aqueous mycelium extract from the Basidiomycete *Pleurotus ostreatus* mushroom. *Nat. Prod. Res.* 2015;29:1557-1561. [doi:10.1080/14786419.2014.983918](https://doi.org/10.1080/14786419.2014.983918).
34. Llauradó G. Evaluación de la actividad inmunomoduladora de bioproductos obtenidos de la seta comestible *Pleurotus* sp. Tesis de Doctor en Ciencias de la Salud (Ph.D.). Centro de Estudios de Biotecnología Industrial, Universidad de Oriente. Santiago de Cuba, Cuba; 2016. (in Spanish).
35. Biziulevicius GA, Kislukhina OV, Kazlaukaitė J., Zukaitė V. Food-protein enzymatic hydrolysates possess both antimicrobial and immunostimulatory activities: a 'cause and effect' theory of bifunctionality. *FEMS Immunol Med Microbiol.* 2006;46:131-138. [doi:10.1111/j.1574-695X.2005.00019.x](https://doi.org/10.1111/j.1574-695X.2005.00019.x).
36. Cheung LM, Cheung PCK, Ooi VCE. Antioxidant activity and total phenolics of edible mushroom extracts. *Food Chem.* 2003;81:249-255.
37. Choi Y., Lee SM, Chun J., Lee HB, Lee J. Influence of the heat treatment on the antioxidant activities and polyphenolic compounds of shiitake (*Lentinus edodes*) mushroom. *Food Chem.* 2006;99:381-387. [doi:10.1016/S0308-8146\(02\)00419-3](https://doi.org/10.1016/S0308-8146(02)00419-3).
38. Lee YL, Huang GW, Liang ZC, Mau JL. Antioxidant properties of three extracts from *Pleurotus citrinopileatus*. *LWT-Food Sci Technol.* 2007;40:823-833. [doi:10.1016/j.lwt.2006.04.002](https://doi.org/10.1016/j.lwt.2006.04.002).
39. Okhawa H., Ohishi N., Yagi K. Assay of lipid peroxides in animal tissue by thiobarbituric acid reaction. *Anal Biochem.* 1979;95:351-358.
40. Morris HJ, Lebeque Y., Fontaine R., Bermúdez RC, Llauradó G., Marcos J. A note on the *in vitro* macrophage-stimulating activity of water-soluble extracts from mycelium of *Pleurotus* spp. *Food Agric Immunol.* 2007;18(1):31-37. [doi:10.1080/09540100701248631](https://doi.org/10.1080/09540100701248631).
41. Chermahini SH, Majid FAA. Cosmeceutical values, antimicrobial activities and antioxidant properties of cashew leaves extract. *Afr J Biotechnol.* 2011;10(65):14573-14582.
42. Cabrera RL, Díaz RL, Fernández NT, Bravo FL. Susceptibilidad antimicrobiana de aislamientos bacterianos causantes de infecciones comunitarias. *Rev Cubana Med Gen Integr.* 2007;23(1) Available in: <http://scielo.sld.cu/scielo.php>.
43. Dharmaraj K., Kuberan T., Mahalakshmi R. Comparison of nutrient contents and antimicrobial properties of *Pleurotus djamor*, *Agaricus bisporus* and *Ganoderma tsugae*. *Int J Curr Microbiol Appl Sci.* 2014;3:518-526. Available in: <http://www.ijcmas.com>.
44. Chowdhury MMH, Kubra K., Ahme SR. Screening of antimicrobial, antioxidant properties and bioac-

- tive compounds of some edible mushrooms cultivated in Bangladesh. *Annals Clin Microbiol Antimicrob*. 2015;14:8. [doi:10.1186/s12941-015-0067-3](https://doi.org/10.1186/s12941-015-0067-3).
45. Cowan MM. Plant products as antimicrobial agents. *Clin Microbiol Rev*. 1999;12:564-582.
46. Llauradó G, Farnet Da Silva AM, Hersens D, Gaime-Perraud I, Morris HJ, Moukha SM *In vitro* comparative study of the influence of mycochemical composition of *Pleurotus* sp. crude extracts on the growth of tumoral cell lines. *Comunicaciones de la 21 Conferencia de Química*. Santiago de Cuba, Cuba. Diciembre 3-5; 2014.
47. Fulda S. Cell death in haematological tumors. *Apoptosis* 2009;14:409-423. [doi:10.1007/s10495-008-0306-6](https://doi.org/10.1007/s10495-008-0306-6).
48. Sarangi I, Ghosh D, Bhutia SK, Mallick SK, Maiti TK. Anti-tumor and immunomodulating effects of *Pleurotus ostreatus* mycelia-derived proteoglycans. *Int Immunopharmacol*. 2006; 6:1287-1297. [doi:10.1016/j.intimp.2006.04.002](https://doi.org/10.1016/j.intimp.2006.04.002).
49. Lee ChL, Yang X., Wan JMF. The culture duration affects the immunomodulatory and anticancer effect of polysaccharopeptide derived from *Coriolus versicolor*. *Enzyme Microb Tech*. 2006;38:14-21. [doi:10.1016/j.enzmictec.2004.10.009](https://doi.org/10.1016/j.enzmictec.2004.10.009).
50. Gu YH, Belury MA. Selective induction of apoptosis in murine skin carcinoma cells (CH72) by an ethanol extract of *Lentinula edodes*. *Cancer Lett*. 2005;220:21-28. [doi:10.1016/j.canlet.2004.06.037](https://doi.org/10.1016/j.canlet.2004.06.037).
51. Harhaji L., Mijatovic S., Maksimov-Ivanic D., et al. Anti-tumor effect of *Coriolus versicolor* methanol extract against mouse B16 melanoma cells: *in vitro* and *in vivo* study. *Food Chem Toxicol*. 2008;46:1825-1833. [doi:10.1016/j.fct.2008.01.027](https://doi.org/10.1016/j.fct.2008.01.027).
52. Jayakumar T., Thomas PA, Sheu JR, Geraldine P. *In-vivo* and *in-vivo* antioxidant effects of the oyster mushroom *Pleurotus ostreatus*. *Food Res Int*. 2011;44:851-861. [doi:10.1016/j.foodres.2011.03.015](https://doi.org/10.1016/j.foodres.2011.03.015).
53. Rajeshwar Y., Senthil Kumar GP, Gupta M., Upal Kanti M. Studies on *In vitro* antioxidant activities of methanol extract of *Mucuna pruriens* (Fabaceae) seeds. *Eur Bull Drug Res*. 2005;13:31-39.
54. Asatiani MD, Elisashvili V., Songulashvili G., Reznick AZ, Wasser S.P. (2010). Higher Basidiomycetes mushrooms as a source of antioxidants. In: Rai M, Kövics G. (Eds.). *Progress in Mycology* Jodhpur: Scientific Publishers/Springer; p. 311-326.
55. Kuskoski E., Asuero A, Troncoso A, Manzini-Filho J, Fett R. Aplicación de diversos métodos químicos para determinar actividad antioxidante en pulpa de frutos. *Cienc Tecnol Aliment*. 2005;25(4):726-732.
56. Batista PL. Evaluación *in vitro* de las potencialidades antimicrobianas y antioxidantes de extractos crudos de polisacáridos de *Pleurotus* sp. Tesis de Master en Biotecnología. Centro de Estudios de Biotecnología Industrial, Universidad de Oriente. Santiago de Cuba, Cuba; 2016. (in Spanish).
57. De Bruijn J, Loyola C, Aqueveque P, Cañumir J, Cortéz M, France A. Antioxidant properties of extracts obtained from *Grifola gargar* mushrooms. *Micol Apl Int*. 2009;21(1):11-18.
58. Zhang H., Wang ZY, Yang X., Wang X., Zhang Z. *In vitro* antioxidant activities of sulfated derivatives of polysaccharides extracted from *Auricularia auricular*. *Int J Mol Sci*. 2011;12(5): 3288-3302. [doi:10.3390/ijms12053288](https://doi.org/10.3390/ijms12053288).
59. De Bruijn J, Loyola C, Aqueveque P, Cañumir J, Cortéz M, France A. Influence of heat treatment on the antioxidant properties of *Grifola gargar* hydro-alcoholic extracts. *Micol Apl Int*. 2008;20(1):27-34.
60. Lü IM, Lin PH, Yao Q, Chen Ch. Chemical and molecular mechanisms of antioxidants: Experimental approaches and model systems. *Cell Mol Med*. 2010;14(4):840-860. [doi:10.1111/j.1582-4934.2009.00897.x](https://doi.org/10.1111/j.1582-4934.2009.00897.x).
61. Jayakumar T, Thomas PA, Geraldine P. antioxidant activities of an ethanolic extract of the oyster mushroom, *Pleurotus ostreatus*. *Innov Food Sci Emerg Technol*. 2009;102:228-234. [doi:10.1016/j.ifset.2008.07.002](https://doi.org/10.1016/j.ifset.2008.07.002).
62. Niki E. Assessment of antioxidant capacity *In vitro* and *in vivo*. *Free Radic Biol Med*. 2010;49(4):503-515. [doi:10.1016/j.freeradbiomed.2010.04.016](https://doi.org/10.1016/j.freeradbiomed.2010.04.016).
63. Konyalioglu S., Karamenderes C. The protective effects of *Achillea* L. species native in Turkey against H<sub>2</sub>O<sub>2</sub>-induced oxidative damage in human erythrocytes and leukocytes. *J Ethnopharmacol*. 2005;102:221-227. [doi:10.1016/j.jep.2005.06.018](https://doi.org/10.1016/j.jep.2005.06.018).
64. Kozarski M., Klaus A., Nikšić M., et al. **Antioxidative activities and chemical characterization of polysaccharide extracts from the widely used mushrooms *Ganoderma applanatum*, *Ganoderma lucidum*, *Lentinus edodes* and *Trametes versicolor***. *J Food Compos Anal*. 2012;26:144-153. [doi:10.1016/j.jfca.2012.02.004](https://doi.org/10.1016/j.jfca.2012.02.004).
65. Wu Y., Choi MH, Li J., Yang H., Shin HJ. Mushroom cosmetics: the present and future. *Cosmetics*. 2016;3:22. [doi:10.3390/cosmetics3030022](https://doi.org/10.3390/cosmetics3030022).
65. Hankook Sansim Firming Cream (Tan Ryuk SANG), <http://bestkoreanbeautyproducts.blogspot.com/2008/10/hankook-sansim.html> (Accessed Jun 8, 2016).